Hours

Minutes

Seconds

-40%

on all subscriptions*

Last hours

Enjoy this offer

* See conditions under "Our services"

Last Transcript: Vivesto AB

Vivesto AB - Special Call

11-24

More transcripts

Analysts' recommendations: Vivesto AB

05-26	DNB Carnegie adjusts Vivesto fair value following reverse stock split	FW
11-21	DNB Carnegie Lowers Target Value for Vivesto Following Rights Issue Announcement	FW
13/08/25	DNB Carnegie Lowers Target Value for Vivesto as Costs Expected to Remain Steady	FW
09/07/24	Paccal Vet analysis could raise the temperature for Vivesto - Penser	FW
30/12/22	Orrön Energy the year's best and Isofol Medical the year's worst share on Nasdaq Stockholm	FW

More recommendations

News in other languages: Vivesto AB

25/03/20	Oasmia Pharmaceutical AB (publ) : un partenariat stratégique pour la distribution d'Apealea
30/01/20	Oasmia Pharmaceutical AB (publ) : Apealea arrive sur les marchés scandinaves

More news

Managers and Directors: Vivesto AB

Manager	Title	Age	Since
Erik Kinnman CEO	Chief Executive Officer	68	23/01/2023
Robert Maiorana DFI	Director of Finance/CFO	66	01/07/2022
Teresa Fernandez Zafra CTO	Chief Tech/Sci/R&D Officer	39	01/01/2023

Director	Title	Age	Since
Isak Peter Zonabend CHM	Chairman	46	25/05/2022
Hege Hellstrom BRD	Director/Board Member	61	26/09/2019
Pål Ryfors BRD	Director/Board Member	43	25/05/2022

More insiders

Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.

Employees

Sector

Pharmaceuticals

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Cap	99.09M 10.34M 9.02M 8.35M 7.82M 14.66M 976M 14.75M 38.4M 480M 38.83M 37.99M 1.67B	P/E 2026 *	-2.92x	P/E 2027 *	-2.14x
Enterprise Value	91.09M 9.51M 8.29M 7.68M 7.19M 13.48M 897M 13.56M 35.3M 442M 35.69M 34.93M 1.53B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	56.4%	Yield 2026 *	-	Yield 2027 *	-

06-16	Vivesto AB Reports Positive Results From Intravenous Cantrixil Pharmacokinetic And Toxicology Study	CI
06-16	Vivesto reports positive results for intravenous Cantrixil	FW
06-05	Sweden's Vivesto Names New Finance Chief	MT
06-05	Vivesto appoints Björn Svanström as new CFO	FW
06-05	Vivesto AB Announces Chief Financial Officer Changes	CI
05-26	DNB Carnegie adjusts Vivesto fair value following reverse stock split	FW
05-20	Vivesto trades on Nasdaq Stockholm today following 1:100 reverse stock split	FW
05-20	Calendar Wednesday May 20	FW
05-13	Vivesto sets record date for reverse share split as May 21, 2026	RE
05-13	Vivesto sets timetable for reverse stock split	FW
05-07	Vivesto Q1 operating result of SEK -6.8 mln	RE
05-07	Vivesto reports narrowed operating loss	FW
04-01	Sweden's Vivesto Plans Reverse Share Split, Share Capital Reduction	MT

06-16	Vivesto: Positive data for Cantrixil	AQ
06-16	Vivesto reports positive results from i.v. Cantrixil PK/toxicology study	AQ
06-05	Vivesto appoints Björn Svanström as CFO	AQ
05-29	New number of shares and votes in Vivesto	AQ
05-26	Vivesto: Minor model adjustments	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VIVESTO AB	-.--%	-99.00%	-	-	10.34M
ELI LILLY AND COMPANY	-1.21%	-3.04%	+44.03%	+143.07%	980B
JOHNSON & JOHNSON	-2.48%	-5.18%	+52.47%	+39.15%	550B
ABBVIE INC.	-2.14%	-4.94%	+16.83%	+57.08%	382B
ROCHE HOLDING AG	+0.25%	-3.09%	+23.33%	+16.04%	316B
ASTRAZENECA PLC	+0.61%	-1.69%	+27.35%	+13.73%	272B
NOVARTIS AG	+0.22%	-3.10%	+24.67%	+30.49%	268B
NOVO NORDISK A/S	+4.59%	+1.98%	-38.43%	-46.26%	199B
AMGEN INC.	-1.19%	-4.95%	+16.68%	+47.69%	182B
GILEAD SCIENCES, INC.	-1.35%	-1.46%	+14.06%	+59.26%	154B
Average	-0.27%	-3.02%	+20.11%	+40.03%	366.93B
Weighted average by Cap.	-0.78%	-3.68%	+29.49%	+63.31%

	2026 *	2027 *
Net sales	-	-
Net income	-31M -3.24M -2.82M -2.61M -2.45M -4.59M -305M -4.62M -12.01M -150M -12.15M -11.89M -522M	-46M -4.8M -4.19M -3.88M -3.63M -6.81M -453M -6.85M -17.83M -223M -18.02M -17.64M -774M
Net Debt	-8M -835K -728K -674K -631K -1.18M -78.8M -1.19M -3.1M -38.79M -3.13M -3.07M -135M	-10M -1.04M -910K -843K -789K -1.48M -98.5M -1.49M -3.88M -48.48M -3.92M -3.83M -168M

Vivesto AB Stock OTC Markets

Stocks

OASMY

US67421W1099

Pharmaceuticals

Valuation: Vivesto AB

Chart: Vivesto AB

Latest news : Vivesto AB

Last Transcript: Vivesto AB

Analysts' recommendations: Vivesto AB

Press Releases: Vivesto AB

News in other languages: Vivesto AB

Managers and Directors: Vivesto AB

Other Pharmaceuticals

Financials

Company Profile